<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02757677</url>
  </required_header>
  <id_info>
    <org_study_id>GR-02</org_study_id>
    <nct_id>NCT02757677</nct_id>
  </id_info>
  <brief_title>Evaluation of Blood Flow Characteristics in Glaucoma Using Optical Coherence Tomography Angiography (OCT-A).</brief_title>
  <official_title>A Cross-sectional, Prospective, Observational Study to Evaluate Blood Flow Characteristics in Glaucoma Patients Using Optical Coherence Tomography Based Angiography (OCT-A).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Vision Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Vision Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to evaluate the efficacy of the new Optical Coherence Tomography based
      Angiography (OCT-A) softwares in the diagnosis and management of glaucoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Macular and optic nerve head bloodflow, as measured by OCT-A macular and optic nerve head vessel density (%)</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Longitudinal arm</arm_group_label>
    <description>Evaluate optic nerve head blood flow using the new OCT-A software in surgically and medically treated glaucoma patients and in different types of glaucoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24-h Intraocular pressure (IOP) arm</arm_group_label>
    <description>Evaluate the correlation between circadian IOP changes and optic nerve head blood flow using the new OCT-A software</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery arm</arm_group_label>
    <description>Evaluate blood flow using the new OCT-A software in surgically treated glaucoma patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optical Coherence Tomography based Angiography</intervention_name>
    <description>A contrast-free, noninvasive technology to identify blood vessels in the eye</description>
    <arm_group_label>Longitudinal arm</arm_group_label>
    <arm_group_label>24-h Intraocular pressure (IOP) arm</arm_group_label>
    <arm_group_label>Surgery arm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients will be enrolled from glaucoma clinics of the Montchoisi glaucoma center.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of open angle glaucoma (OAG) including pseudo-exfoliative and pigmentary
             glaucoma.

          -  Documented glaucomatous visual field damage (in the previous 12 months with mean
             defect (MD) &gt; 2.0 dB)

          -  Structural and/or functional glaucomatous damage

          -  Have given written informed consent, prior to any investigational procedures

        Exclusion Criteria:

          -  Patients with allergy to corneal anesthetic

          -  Patients not able to understand the character and individual consequences of the
             investigation

          -  Participation in other clinical research within the last 4 weeks

          -  Other diseases that may cause visual field loss or optic disc abnormalities

          -  Refractive error of &gt; +3.00D or &lt; -7.00D
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kaweh Mansouri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glaucoma center, Montchoisi clinic, Swiss vision network</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kaweh Mansouri, MD</last_name>
    <phone>0041791767267</phone>
    <email>kmansouri@gsvn.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Glaucoma center, Montchoisi clinic</name>
      <address>
        <city>Lausanne</city>
        <zip>1006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaweh Mansouri, MD</last_name>
      <phone>0041791767267</phone>
      <email>kmansouri@gsvn.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2016</study_first_submitted>
  <study_first_submitted_qc>April 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <last_update_submitted>April 27, 2016</last_update_submitted>
  <last_update_submitted_qc>April 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Swiss Vision Network</investigator_affiliation>
    <investigator_full_name>dr. Kaweh Mansouri</investigator_full_name>
    <investigator_title>dr. Kaweh Mansouri</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

